Revium Rx. (RVRC)

OTCMKTS · Delayed Price · Currency is USD
1.670
+0.170 (11.33%)
Mar 6, 2026, 4:00 PM EST
316.36%
Market Cap 91.09M
Revenue (ttm) n/a
Net Income (ttm) -2.08M
Shares Out 60.73M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1
Average Volume 269
Open 1.670
Previous Close 1.500
Day's Range 1.670 - 1.670
52-Week Range 0.500 - 1.670
Beta -0.59
RSI 47.71
Earnings Date n/a

About Revium Rx.

Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors. The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination. The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; no... [Read more]

Sector Healthcare
Founded 1997
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol RVRC
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.